ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02404350
Recruitment Status : Active, not recruiting
First Posted : March 31, 2015
Last Update Posted : February 1, 2018
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of this study is to demonstrate efficacy including effect on inhibition of progression of structural damage, safety and tolerability up to 2 years with primary focus at Week 16 (week 24 for structural damage), to support the use of secukinumab pre-filled syringe (PFS) by subcutaneous (s.c.) self-administration with or without loading regimen in subjects with active Psoriatic Arthritis (PsA) despite current or previous NSAID, DMARD therapy and/or previous anti-TNFα therapy. Long term efficacy up to 2 years will be based on signs and symptoms of joint/bone structure preservation (X-ray) and improvement in physical function measured by Health Assessment Questionnaire - Disability Index (HAQ-DI©), as well as skin and nail improvement for psoriasis signs.

Condition or disease Intervention/treatment Phase
Psoriatic Arthritis Biological: Secukinumab Phase 3

Detailed Description:

This multicenter study uses a randomized, double-blind, placebo-controlled, parallel-group design. A screening period (SCR) running up to 10 weeks before randomization will be used to assess subject eligibility followed by 104 weeks of treatment.

At BSL approximately 990 subjects whose eligibility is confirmed will be randomized to one of four treatment groups in 2:2:2:3 ratio:

  • Group 1 - secukinumab 150 mg s.c. without loading regimen
  • Group 2 - secukinumab 150 mg s.c. with loading dose regimen
  • Group 3 - secukinumab 300 mg s.c. with loading dose regimen
  • Group 4 - Placebo s.c. NOTE: Group 4 is split into 2 treatment arms, detailed description below. At randomization, subjects will be stratified on the basis of previous anti-TNF therapy as TNFα inhibitor naïve (TNF-naïve) or TNFα inhibitor inadequate responders (TNF-IR).

At each study treatment visit, one (for secukinumab 150 mg) or two (for secukinumab 300 mg) s.c. injections in the form of PFS will be administered, since secukinumab is available in 1.0 mL (150 mg) PFSs. Placebo to secukinumab is also available in 1.0 mL to match the active drug.

At Week 16, subjects who have been randomized to secukinumab groups at BSL (Groups 1-3) will be classified as either responders (≥20% improvement from BSL in both tender joint count (TJC) and swollen joint counts (SJC)) or non-responders (<20% improvement from BSL TJC or SJC), however they will continue on the same treatment irrespective of their response status.

At Week 16, subjects who have been randomized to placebo at BSL (Group 4) will be classified as either responders (≥20% improvement from BSL in both TJC and SJC) or non-responders (<20% improvement from BSL TJC or SJC):

  • Subjects who are non-responders will receive either secukinumab 150 mg or 300 mg s.c. every 4 weeks starting at Week 16 (as dictated by treatment sequence assigned to these subjects at BSL).
  • Subjects who are responders will continue to receive placebo every 4 weeks. Starting Week 24, these subjects will receive either secukinumab 150 mg s.c. or 300 mg s.c. every 4 weeks starting at Week 24 (as dictated by treatment sequence assigned to these subjects at BSL).

At Week 24, the assessments to address the primary objective will be performed. As described above, subjects who are still receiving placebo s.c. injection will receive either secukinumab 150 mg s.c. or 300 mg s.c. every 4 weeks starting at Week 24 (as dictated by treatment sequence assigned to these subjects at BSL).

At week 52, based on Investigator's decision, the subjects on a 150 mg doses whose sign and symptoms do not show satisfactory response have the possibility to be allocated to secukinumab 300 mg s.c.

After the Week 52 database lock and analyses have been completed, site personnel and subjects will be unblinded to the original randomized treatment (sequence) assignment at randomization. In addition, treatment will be given open-label in order to eliminate the placebo injection. The subject will continue to receive the same active dose of secukinumab as open-label treatment administered until Week 100.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 998 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-blind, Placebo Controlled Multi-center Study of Subcutaneous Secukinumab (150 mg and 300 mg) in Prefilled Syringe to Demonstrate Efficacy (Including Inhibition of Structural Damage), Safety, and Tolerability up to 2 Years in Subjects With Active Psoriatic Arthritis (FUTURE 5)
Actual Study Start Date : August 31, 2015
Actual Primary Completion Date : August 16, 2017
Estimated Study Completion Date : January 16, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Secukinumab

Arm Intervention/treatment
Experimental: Secukinumab 150 mg load (Group 1)

Secukinumab 150 mg sc injection every week for 4 weeks followed by Secukinumab 150 mg every 4 weeks for 100 weeks

Beginning at Week 52, for subjects whose signs and symptoms are not fully controlled, and who the investigator believes may improve further with an increase in dose, may have the secukinumab dose increased to 300mg s.c. every 4 weeks.

Biological: Secukinumab
Anti IL-17a monoclonal antibody

Experimental: Secukinumab 150 mg no load (Group 2)

Secukinumab 150 mg sc injection every 4 weeks for 100 weeks

Beginning at Week 52, for subjects whose signs and symptoms are not fully controlled, and who the investigator believes may improve further with an increase in dose, may have the secukinumab dose increased to 300mg s.c. every 4 weeks.

Biological: Secukinumab
Anti IL-17a monoclonal antibody

Experimental: Secukinumab 300 mg load (Group 3)
Secukinumab 300 mg sc injection every week for 4 weeks followed by Secukinumab 300 mg every 4 weeks for 100 weeks
Biological: Secukinumab
Anti IL-17a monoclonal antibody

Placebo Comparator: Placebo arm 1 (Group 4)

Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders will be switched to Secukinumab either 150 or 300 mg sc injection every two weeks until week 100. Responders at week 16 will continue receiving placebo until week 24, then will be switched to secukinumab 150 or 300 mg sc injection every 4 weeks for 100 weeks. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)

Beginning at Week 52, for subjects whose signs and symptoms are not fully controlled, and who the investigator believes may improve further with an increase in dose, may have the secukinumab dose increased to 300mg s.c. every 4 weeks.

Biological: Secukinumab
Anti IL-17a monoclonal antibody

Placebo Comparator: Placebo arm 2 (Group 4)

Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders will be switched to Secukinumab either 150 or 300 mg sc injection every two weeks until week 100. Responders at week 16 will continue receiving placebo until week 24, then will be switched to secukinumab 150 or 300 mg sc injection every 4 weeks for 100 weeks. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)

Beginning at Week 52, for subjects whose signs and symptoms are not fully controlled, and who the investigator believes may improve further with an increase in dose, may have the secukinumab dose increased to 300mg s.c. every 4 weeks.

Biological: Secukinumab
Anti IL-17a monoclonal antibody




Primary Outcome Measures :
  1. American College of Rheumatology 20 (ACR20) response at Week 16 [ Time Frame: week 0 - 16 ]
    The analysis of the primary efficacy variable will be based on the FAS subjects. Primarily, CRP will be used instead of ESR to calculate ACR response; ESR will only be used in the event CRP is missing.


Secondary Outcome Measures :
  1. Van der Heijde modified total Sharp score at Week 24. The method includes, in each hand and foot, evaluations of areas for erosions and areas for joint space narrowing [ Time Frame: Week 0- 24 ]
    Change from baseline in van der Heijde modified total Sharp score at Week 24

  2. Psoriasis Area and Severity Index 75 (PASI75) response at Week 16 [ Time Frame: Week 0-16 ]
    PASI75 response at Week 16

  3. Psoriasis Area and Severity Index 90 (PASI90) response at Week 16 [ Time Frame: Week 0-16 ]
    PASI90 response at Week 16

  4. American College of Rheumatology 50 (ACR50) response at Week 16 [ Time Frame: Week 0-16 ]
    ACR50 response at Week 16

  5. Health assessment questionnaire disability index© (HAQ-DI©) score at Week 16 [ Time Frame: Week 0-16 ]
    Change from baseline in HAQ-DI© score at Week 16

  6. Disease Activity Score 28 Joints (DAS28-CRP) at Week 16 [ Time Frame: Week 0-16 ]
    Change from baseline in DAS28-CRP at Week 16

  7. Enthesitis at Week 16 [ Time Frame: Week 0-16 ]
    Presence of enthesitis at Week 16

  8. Dactylitis at Week 16 [ Time Frame: Week 0-16 ]
    Presence of dactylitis at Week 16



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months with moderate to severe PsA who must have at BSL ≥3 tender joints out of 78 and ≥3 swollen joints out of 76 (dactylitis of a digit counts as one joint each). - Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies negative at screening. - Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis or a documented history of plaque psoriasis. - Subjects with PsA should have taken NSAIDs for at least 4 weeks prior to randomization with inadequate control of symptoms or at least one dose if stopped due to intolerance to NSAIDs.-Subjects who are regularly taking NSAIDs as part of their PsA therapy are required to be on a stable dose for at least 2 weeks before study randomization and should remain on a stable dose up to Week 24. - Subjects taking corticosteroids must be on a stable dose of ≤10 mg/day prednisone or equivalent for at least 2 weeks before randomization and should remain on a stable dose up to Week 24. - Subjects taking MTX (≤ 25 mg/week) are allowed to continue their medication if the dose is stable for at least 4 weeks before randomization and should remain on a stable dose up to Week 52. - Subjects on MTX must be on folic acid supplementation at randomization. - Subjects who are on a DMARD other than MTX must discontinue the DMARD 4 weeks prior to randomization visit except for leflunomide, which has to be discontinued for 8 weeks prior to randomization unless a cholestyramine wash-out has been performed.

  • Subjects who have been on a TNFα inhibitor must have experienced an inadequate response to previous or current treatment with a TNFα inhibitor given at an approved dose for at least 3 months or have stopped treatment due to safety/tolerability problems after at least one administration of a TNFα inhibitor.
  • Subjects who have previously been treated with TNFα inhibitors (investigational or approved) will be allowed entry into study after appropriate wash-out period prior to randomization

Exclusion Criteria:

Chest X-ray or chest MRI with evidence of ongoing infectious or malignant process. - Subjects taking high potency opioid analgesics. - Previous exposure to secukinumab or other biologic drug directly targeting IL-17 or IL-17 receptor. - Ongoing use of prohibited psoriasis treatments / medications (e.g., topical corticosteroids, UV therapy) at randomization. - Any intramuscular or intravenous or intra-articular corticosteroid treatment within 4 weeks before randomization. - Subjects who have ever received biologic immunomodulating agents except for those targeting TNFα (investigational or approved). - Previous treatment with any cell-depleting therapies including but not limited to anti- CD20, investigational agents - Other protocol-defined exclusion criteria do apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02404350


  Show 171 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02404350     History of Changes
Other Study ID Numbers: CAIN457F2342
First Posted: March 31, 2015    Key Record Dates
Last Update Posted: February 1, 2018
Last Verified: January 2018

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Psoriatic Arthritis, Arthritis, Psoriatic, Psoriatic Arthropathy

Additional relevant MeSH terms:
Arthritis
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spondylarthropathies
Spondylarthritis
Spondylitis
Spinal Diseases
Bone Diseases
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs